Metabolic Imaging Predict Histopathologic Response to Preop ChemoXRT for Locally Advanced Rectal CA

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT00394615
• Date of registration: 05/07/2006
• Primary sponsor: Stanford University
• Public title: Metabolic Imaging Predict Histopathologic Response to Preop ChemoXRT for Locally Advanced Rectal CA
• Scientific title: Metabolic Imaging: Predicting Histopathologic Response to Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer
• Date of first enrolment: October 2003
• Target sample size: 15
• Recruitment status: Terminated
• URL: http://clinicaltrials.gov/show/NCT00394615
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Countries of recruitment

United States

Contacts

• Name: Albert Koong
• Affiliation: Stanford University

Key inclusion & exclusion criteria

Inclusion Criteria:- You must be diagnosed with locally advanced rectal cancer and have
chosen treatment with preoperative chemoradiotherapy followed by surgery, which is a
standard treatment approach for this disease.

Exclusion Criteria:- You are ineligible for this study if you are pregnant or under the
age of 18 years old.



Age minimum: 18 Years
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Rectal Cancer

Intervention(s)

Procedure: Metabolic Imaging

Primary Outcome(s)

To learn whether new medical imaging technology can help predict the response of rectal cancer to preoperative chemotherapy and radiation therapy. [Time Frame: not known]

Secondary ID(s)

REC0001

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Stanford Cancer Council